|05 December, 2019

Egypt's Rameda private placement oversubscribed 1.17 fold

The company offered 49% stake of its share, 357.77mln shares to institutional investors through an international offering, and 18.83mln shares to retail investors in Egypt

A man is seen at Dubai Financial Market in Dubai, United Arab Emirates September 16, 2019. Image used for illustrator purpose

A man is seen at Dubai Financial Market in Dubai, United Arab Emirates September 16, 2019. Image used for illustrator purpose

REUTERS/Christopher Pike

 Rameda Pharmaceutical private placement on the Egyptian Exchange (EGX) was oversubscribed 1.17 fold, the company said in a statement on Wednesday. 

Egypt’s second private-sector initial public offering (IPO) of the year, revitalising the country’s lacklustre IPO market, is the largest Egyptian IPO and has been since 2015. 

 

 The company offered 49% stake of its share, 357.77m shares to institutional investors through an international offering, and 18.83m shares to retail investors in Egypt. Shares were priced at EGP 4.66 ($0.29) each.

Rameda will have a capital of EGP3.6bn ($222m) once the initial public offering is completed.

The group’s senior management intends to use the net proceeds of the closed subscription to fund operational expansion, principally through molecule acquisitions but also through the opportunistic acquisition of pharmaceutical companies.

HSBC and Investec are joint global coordinators and bookrunners for the international offering, while CI Capital is joint bookrunner. Compass Capital is the IPO advisor, and Inktank is investor relations advisor.

© 2019 Daily News Egypt. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Equities